The vote outcome is critical — if the charter amendment fails, the 49.3M common warrants become worthless, which could trigger a sharp sell-off from warrant holders and potentially impair the company's ability to raise future capital. Monitor proxy advisory firm recommendations (ISS/Glass Lewis) and early vote tallies. The special meeting is November 13, 2026.
Price Chart
Executive Summary
Pyxis Oncology is holding a special meeting on November 13, 2026 to seek stockholder approval to double its authorized common shares from 190M to 380M. The increase is needed to allow exercise of 49.3M common warrants issued in an October 1, 2026 underwritten offering. Without approval, those warrants would be worthless. The filing also includes an adjournment proposal to solicit additional votes if needed.
Key Facts
- Proposes to increase authorized common shares from 190,000,000 to 380,000,000 (2x increase)
- 119,583,637 shares outstanding as of October 8, 2026 record date
- October 1, 2026 offering sold 36,047,919 shares + 1,883,121 pre-funded warrants + 49,310,352 common warrants
- Only ~27.6M authorized shares remain available; insufficient to permit warrant exercise
- If charter amendment fails, the 49.3M common warrants will not be exercisable and may have no value
- Board can abandon the amendment even if stockholders approve
- Five 5%+ holders: GordonMD (16.4%), BVF (9.99%), RTW (8.4%), OrbiMed (7.2%), Pfizer (5.9%)
- Insiders and directors as a group own 10.5% of outstanding shares
Financial Impact
Potential dilution of up to ~41% if all 49.3M warrants are exercised on top of the 36M shares already issued in the October 1 offering. The company is a clinical-stage oncology company with no disclosed revenue, so dilution is the primary financial impact.
Risk Factors
- Charter amendment fails → warrants worthless, potential stock price decline
- Massive dilution if all warrants exercised (up to 49.3M additional shares)
- Clinical-stage biotech with no disclosed revenue; dependent on capital markets
- Board can abandon amendment even if approved, creating uncertainty
- Anti-takeover potential: increased authorized shares could be used to dilute hostile bidders
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001193125-26-427882 |
| Document: 0001193125-26-427882-index-headers.html | 0001193125-26-427882 |
| Document: 0001193125-26-427882-index.html | 0001193125-26-427882 |
| Document: 0001193125-26-427882.txt | 0001193125-26-427882 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Press Release | $1.66 | awaiting T+5 | — | $1.74 (+4.52%) |
Oct 21, 2026 5d ago | DEF 14A | $1.71 | awaiting T+5 | — | $1.74 (−1.46%) |
Oct 9, 2026 17d ago | SC 13G/A | $2.03 $1.68 | ▼ −17.24% | ▼ −15.27% | $1.74 (−14.53%) |
Oct 2, 2026 25d ago | SC 13G/A | $2.14 $2.03 | ▼ −5.14% | ▼ −6.30% | $1.74 (−18.93%) |
Oct 2, 2026 25d ago | Press Release | $2.14 $2.03 | ▲ +5.14% | ▲ +6.30% | $1.74 (+18.93%) |
Oct 1, 2026 25d ago | 8-K | $2.14 $2.03 | ▲ +5.14% | ▲ +6.30% | $1.74 (+18.93%) |
Oct 1, 2026 26d ago | 424B5 | $2.19 $1.99 | ▲ +9.13% | ▲ +10.43% | $1.74 (+20.78%) |
Sep 30, 2026 27d ago | Press Release | $2.33 $2.01 | ▲ +13.73% | ▲ +15.65% | $1.74 (+25.54%) |
Sep 9, 2026 6w ago | 8-K | $3.38 $3.34 | ▼ −1.18% | ▼ −0.09% | $1.74 (−48.67%) |
Sep 8, 2026 7w ago | 8-K | $3.89 $3.33 | ▼ −14.40% | ▼ −13.28% | $1.74 (−55.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers